Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.

摘要: ABSTRACTObjective: To compare the metabolic effects of acarbose and repaglinide in type 2 diabetic patients who are being treated with a sulphonylurea–metformin combination therapy. The primary endpoint study was to evaluate which add-on treatment between is more efficacious reducing PPG. second these two global management glucose homeostasis enrolled patients.Research design methods: After 4-week run-in period suplonylurea–metformin combination, 103 were randomised receive addition either repaglinide, up 6 mg/day (2 mg three times day) or acarbose, 300 mg/day (100 mg forced titration (independently their glycaemic control, unless side-effects developed due drug dosage) for 15 weeks. then crossed-over further 12 weeks until 27th week. We assessed body mass index (BMI), glycosylated haemoglo...